How does reduced prostaglandin inhibition protect the stomach?
Rofecoxib (a COX-2 selective inhibitor) reduces production of inflammatory prostaglandins mainly at the site of inflammation, while sparing much of the COX-1–dependent prostaglandin activity that the stomach normally relies on for protection. COX-1–driven prostaglandins help maintain gastric mucosal defenses by supporting mucus and bicarbonate secretion and maintaining adequate mucosal blood flow. When these protective prostaglandins are preserved, the stomach lining is less likely to be damaged, which lowers the risk of ulcers and gastrointestinal bleeding compared with nonselective NSAIDs that inhibit both COX-1 and COX-2.
What specifically goes wrong in the stomach when prostaglandins are suppressed?
Nonselective NSAIDs reduce both protective and inflammatory prostaglandins. In the stomach, that protective prostaglandin drop leads to less mucus and bicarbonate, reduced mucosal blood flow, and impaired repair of minor injuries. The result is a higher likelihood of erosions that can progress to ulcers and bleeding. So the stomach benefit from rofecoxib’s selectivity comes from avoiding the protective prostaglandin suppression that nonselective NSAIDs commonly cause.
How does this explain “better GI tolerance” in practice?
Because rofecoxib preserves more COX-1 activity than traditional NSAIDs, it tends to cause fewer ulcer-related complications and less GI bleeding risk. The stomach protection is not about eliminating drug-related risk entirely; it comes from shifting inhibition away from the COX-1 prostaglandin pathway that supports the gastric barrier.
Does reduced prostaglandin inhibition remove the risk of ulcers completely?
No. Selective COX-2 inhibition lowers GI risk relative to nonselective NSAIDs, but it does not guarantee no stomach injury. Factors such as individual susceptibility and other ulcer risk contributors can still matter, and other effects of NSAID-class drugs (and patient comorbidities) can influence outcomes.
Why does stomach protection matter more than pain relief for some patients?
For people with prior ulcers, GI bleeding risk, advanced age, or other risk factors, preserving gastric prostaglandin-mediated defenses is a key reason COX-2 selective approaches were developed: the goal is to keep anti-inflammatory and pain relief while reducing the stomach toxicity driven by COX-1 prostaglandin inhibition.
Sources
No sources were provided in your prompt, so I can’t cite any specific references.